The National Institute on Drug Abuse (NIDA) mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. 

This charge has two critical components.  The first is the strategic support and conduct of research across a broad range of disciplines.  The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.

Funding Strategy

Funding decisions will be based primarily on the programmatic priorities of the Institute and scientific merit of the application.  NIDA continues to give additional consideration to New Investigators and Early Stage Investigators (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-013.html, http://grants.nih.gov/grants/new_investigators/index.htm).

Information regarding FY 2015 NIH Extramural Financial Operations can be found at:

NIDA has established the following funding policy for FY 2015.

Competing Awards:

NIDA may reduce competing awards from the IRG recommended levels in order to increase the number of awards issued. 

  • New and competing awards will be funded at approximately the same average cost as FY 14.
  • *In general renewal grants should not increase by more than 10% over the prior year’s award.

Non-Competing Continuations Awards:

Consistent with overall NIH policy:

  • Non-competing continuation awards for RPGs and Centers will be funded at 98.5% of committed levels.
  • FY 2015 awards that have already been issued at 90% of committed level will be revised to adjust the award level.
  • Future year commitments will remain unchanged.
  • Ruth L. Kirschstein National Research Service Awards (NRSA) (Fs and Ts) will be funded with 2% stipend increases.

NIDA will continue to support the:

NIH Pathway to Independence Awards (K99/R00) (http://grants.nih.gov/grants/guide/pa-files/PA-15-083.html) which strives to maintain new and talented NIH-supported independent investigators.